San Diego-based Telik Inc. (OTC: TELK), a clinical stage oncology drug development company that recently merged with MabVax Therapeutics Inc. has announced the appointment of seven new members to its board of directors.
The new board members are Jim J. Antonopoulos, Kenneth M. Cohen, J. David Hansen, Dr. Philip O. Livingston, Paul V. Maier, Dr. Jeffrey V. Ravetch and Dr. Michael M. Wick.
The company hopes these appointees will help guide the company and its management in developing an expanded product development pipeline post-merger.
“We are pleased to be able to attract such an outstanding new slate of board members who have both strong scientific backgrounds and demonstrated corporate leadership success at public life sciences companies,” David Hansen, president and CEO. “We are proud to acknowledge our new board members are associated with leading edge research institutions and academia in our field of interest related to novel therapies using cancer vaccines and antibodies.”